These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27843596)

  • 1. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.
    Liede A; Hallett DC; Hope K; Graham A; Arellano J; Shahinian VB
    ESMO Open; 2016; 1(2):e000040. PubMed ID: 27843596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
    Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
    J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer.
    Preston MA; Ebrahimi R; Hong A; Bobbili P; Desai R; Duh MS; Gandhi R; Hanson S; Dufour R; Morgans AK
    Urol Oncol; 2024 Jul; ():. PubMed ID: 39003108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
    Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
    Wolff JM; Abrahamsson PA; Irani J; da Silva FC
    BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
    Yokomizo A; Koga H; Ito K; Takezawa Y; Komiyama M; Nishimura K; Yonese J; Hashine K; Masumori N; Arai G; Saito S; Shinohara M; Shimizu N; Yamauchi A; Satoh T; Tochigi T; Kobayashi M; Fujimoto H; Kakimoto KI; Fukui I; Tsukamoto T; Nozaki M; Karasawa K; Hasumi M; Ohtani M; Ishiyama H; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Naito S; Yamanaka H;
    Cancer Med; 2021 May; 10(10):3240-3248. PubMed ID: 33932114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
    Payne H; McMenemin R; Bahl A; Greene D; Staffurth J
    Int J Clin Pract; 2019 Sep; 73(9):1-6. PubMed ID: 30414348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of testosterone during androgene deprivation therapy].
    Vallat A; Pillot P; Lebâcle C; Irani J
    Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
    Strum SB; Scholz MC; McDermed JE
    Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
    Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
    Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.
    Tsai HT; Penson DF; Makambi KH; Lynch JH; Van Den Eeden SK; Potosky AL
    Urology; 2013 Aug; 82(2):327-33. PubMed ID: 23896094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.